Search Results - "WAGNER, A. J"

Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy by Stoch, S A, Wagner, J A

“…Osteoporosis is characterized by low bone mass with skeletal fragility and an increased risk of fracture. This bone loss is brought about by an imbalance…”
Get full text

Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug-Drug Interaction Trial Design by Reitman, ML, Chu, X, Cai, X, Yabut, J, Venkatasubramanian, R, Zajic, S, Stone, JA, Ding, Y, Witter, R, Gibson, C, Roupe, K, Evers, R, Wagner, JA, Stoch, A

“…We studied the time course for the reversal of rifampin's effect on the pharmacokinetics of oral midazolam (a cytochrome P450 (CYP) 3A4 substrate) and digoxin…”
Get full text

Calcitonin gene-related peptide: key regulator of cutaneous immunity by Granstein, R. D., Wagner, J. A., Stohl, L. L., Ding, W.

“…Calcitonin gene‐related peptide (CGRP) has been viewed as a neuropeptide and vasodilator. However, CGRP is more appropriately thought of as a pleiotropic…”
Get full text

Biomarkers and Surrogate End Points for Fit-for-Purpose Development and Regulatory Evaluation of New Drugs by Wagner, JA, Williams, SA, Webster, CJ

“…A consistent framework for the acceptance and qualification of biomarkers for regulatory use is needed to facilitate innovative and efficient research and…”
Get full text

Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies by Stoch, SA, Zajic, S, Stone, J, Miller, DL, Van Dyck, K, Gutierrez, MJ, De Decker, M, Liu, L, Liu, Q, Scott, BB, Panebianco, D, Jin, B, Duong, LT, Gottesdiener, K, Wagner, JA

“…Inhibition of cathepsin K (CatK) is a potential new treatment for osteoporosis. In two double‐blind, randomized, placebo‐controlled phase I studies,…”
Get full text

Therapeutic Drug Monitoring as a Component of Personalized Medicine: Applications in Pediatric Drug Development by Momper, J D, Wagner, J A

“…Therapeutic drug monitoring (TDM) is foundational to the concept of personalized medicine. TDM transformed drug therapy by affording the ability to…”
Get full text

The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies by Bloomfield, DM, Kost, JT, Ghosh, K, Hreniuk, D, Hickey, LA, Guitierrez, MJ, Gottesdiener, K, Wagner, JA

“…A number of issues have remained unanswered in the design of “thorough QT” (TQT) studies. In this randomized, placebo‐controlled, two‐period crossover study in…”
Get full text

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib by Ganjoo, K.N., Villalobos, V.M., Kamaya, A., Fisher, G.A., Butrynski, J.E., Morgan, J.A., Wagner, A.J., D'Adamo, D., McMillan, A., Demetri, G.D., George, S.

“…Advanced GISTs are incurable, but often treatable for years with tyrosine kinase inhibitors (TKIs). The majority of GISTs harbor an oncogenic activating…”
Get full text

Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects by Iwamoto, M, Wenning, LA, Petry, AS, Laethem, M, De Smet, M, Kost, JT, Merschman, SA, Strohmaier, KM, Ramael, S, Lasseter, KC, Stone, JA, Gottesdiener, KM, Wagner, JA

“…Raltegravir is a novel human immunodeficiency virus‐1 integrase inhibitor with potent in vitro activity (95% inhibitory concentration (IC95)=33 nM in 50% human…”
Get full text

Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin by Herman, G A, Stein, P P, Thornberry, N A, Wagner, J A

“…Dipeptidyl peptidase‐4 (DPP‐4) inhibitors represent a new class of oral antihyperglycemic agents to treat patients with type 2 diabetes.1 DPP‐4 inhibitors…”
Get full text

Fluctuating lattice Boltzmann by Adhikari, R, Stratford, K, Cates, M. E, Wagner, A. J

“…The lattice Boltzmann algorithm efficiently simulates the Navier-Stokes equation of isothermal fluid flow, but ignores thermal fluctuations of the fluid,…”
Get full text

Accelerating Biomedical Research Through Open Knowledge Creation and Stewardship by Wagner, J A

“…The biomedical research enterprise faces the challenges of decreasing efficiency, escalating costs, and increasing complexity, resulting in reduced return on…”
Get full text

Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1 by Migoya, E M, Bergeron, R, Miller, J L, Snyder, R N K, Tanen, M, Hilliard, D, Weiss, B, Larson, P, Gutierrez, M, Jiang, G, Liu, F, Pryor, K A, Yao, J, Zhu, L, Holst, J J, Deacon, C, Herman, G, Thornberry, N, Amatruda, J, Williams‐Herman, D, Wagner, J A, SinhaRoy, R

“…The aim of the study was to investigate the effects of a dipeptidyl peptidase‐4 (DPP‐4) inhibitor, of metformin, and of the combination of the two agents, on…”
Get full text

Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction by Gutstein, D E, Krishna, R, Johns, D, Surks, H K, Dansky, H M, Shah, S, Mitchel, Y B, Arena, J, Wagner, J A

“…Cholesteryl ester transfer protein (CETP) inhibition is a promising experimental strategy to raise high‐density lipoprotein cholesterol (HDL‐C) and reduce…”
Get full text

Can tuberculosis case finding among health-care seeking adults be improved? Observations from Bissau by Rudolf, F., Haraldsdottir, T. L., Mendes, M. S., Wagner, A-J., Gomes, V. F., Aaby, P., Østergaard, L., Eugen-Olsen, J., Wejse, C.

“…SETTING: The Bandim Health Project study area in Bissau, Guinea-Bissau.OBJECTIVE: To assess the potential usefulness of predictors (elsewhere applied) and…”
Get full text

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells by Johnson, A J, Yeh, Y-Y, Smith, L L, Wagner, A J, Hessler, J, Gupta, S, Flynn, J, Jones, J, Zhang, X, Bannerji, R, Grever, M R, Byrd, J C

“…The cyclin dependent kinase (CDK) inhibitor flavopiridol has demonstrated promising clinical results in relapsed CLL patients leading to efforts to develop…”
Get full text

Tuberculosis case finding and mortality prediction: added value of the clinical TBscore and biomarker suPAR by Rudolf, F., Wagner, A-J., Back, F. M., Gomes, V. F., Aaby, P., Østergaard, L., Eugen-Olsen, J., Wejse, C.

“…SETTING: A suburban area of Bissau, the capital of Guinea-Bissau; the study was conducted among presumptive pulmonary tuberculosis (prePTB) patients seeking…”
Get full text

Being small for gestational age is not an independent risk factor for mortality in neonates with congenital diaphragmatic hernia: a multicenter study by Zenilman, A., Fan, W., Hernan, R., Wynn, J., Abramov, A., Farkouh-Karoleski, C., Aspelund, G., Krishnan, U. S., Khlevner, J., Azarow, K., Crombleholme, T., Cusick, R., Chung, D., Danko, M. E., Potoka, D., Lim, F. Y., McCulley, D. J., Mychaliska, G. B., Schindel, D., Soffer, S., Wagner, A. J., Warner, B. W., Chung, W. K., Duron, V. P.

“…Background Congenital diaphragmatic hernia (CDH) accounts for 8% of all major congenital anomalies. Neonates who are small for gestational age (SGA) generally…”
Get full text

Suppression of Niacin‐induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1 by Lai, E, De Lepeleire, I, Crumley, T M, Liu, F, Wenning, L A, Michiels, N, Vets, E, O'Neill, G, Wagner, J A, Gottesdiener, K

“…Niacin (nicotinic acid) reduces cardiovascular events in patients with dyslipidemia. However, symptoms associated with niacin‐induced vasodilation (e.g.,…”
Get full text

Implications of the Institute of Medicine Report: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease by Wagner, JA, Ball, JR

“…The Institute of Medicine (IOM) released a groundbreaking 2010 report, Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Key recommendations…”
Get full text